
Opinion|Videos|December 25, 2024
Multidisciplinary Treatment Sequencing and Coordination
Author(s)Kevin Kalinsky, MD, MS, Virginia Kaklamani, MD
Panelists discuss their approach to sequencing surgery, radiation, and systemic therapies for early-stage breast cancer patients, emphasizing the guiding principles of treatment sequencing and how individual patient factors influence decisions; they also highlight the importance of multidisciplinary coordination, identifying key specialists, ensuring alignment on diagnosis, risk assessment, and treatment goals, and the critical role of including the patient in these discussions.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Could you explain your approach to sequencing surgery, radiation, and systemic therapies for early-stage patients?
- What principles guide your treatment sequencing recommendations
- To what extent does sequencing vary based on individual patient factors?
- Dr Kalinsky to Dr Kaklamani: What multidisciplinary coordination is vital to optimizing care for patients in this setting?
- Which specialists should be involved, and what is their role on the treatment team?
- How do you ensure the multidisciplinary team is aligned on diagnosis, risk assessment, and treatment goals for each patient?
- What is the importance of including the patient in these treatment goal discussions?
Advertisement
Related to this article

Pankit Vachhani, MD, discusses the importance of hematocrit control in the management of polycythemia vera.

Pembrolizumab plus denosumab produced a 31% ORR and 53% 6-month PFS rate in VEGFR-TKI-pretreated advanced clear cell renal cell carcinoma.

A new study suggests genomic newborn screening could identify children at risk for early cancers and enable earlier diagnosis and less toxic treatment.

The CLDN18.2/CD47 bispecific antibody spevatamig has received FDA fast track designation for advanced and metastatic biliary tract carcinoma.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Hamza Hashmi, MD, discusses the evolving role and implementation of CAR T-cell therapy in early relapsed/refractory multiple myeloma.

The HER2-directed ADC produced confirmed responses across both biomarker-defined cohorts of advanced salivary gland carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
Dr Banerjee on the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
2
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
3
Longer-Term Data Continue to Support Earlier Integration of CAR T-Cell Therapy in R/R Myeloma
4
Trastuzumab Rezetecan Elicits High ORR in HER2-High and HER2-Low Salivary Gland Carcinoma
5

